a-196

A-196 is a potent and selective inhibitor of SUV420h1 and SUV420h2, with IC50 values of 0.025 μM and 0.144 μM, respectively; it is more than 100-fold selective over other histone methyltransferases and non-epigenetic targets.

Denintuzumab-MMAF, an ADC, combines a CD19-directed antibody with McMMAF and is utilized in researching acute lymphoblastic leukemia.

Anti-Human/Mouse CD95 Antibody (HFE7A) is a monoclonal antibody targeting human and mouse CD95 and can be used in cancer and apoptosis research.

Anti-Human/Mouse LY6E Antibody（9B12） is a monoclonal antibody targeting human and mouse LY6E and can be used in cancer research.

Anti-Human/Mouse/Monkey CLDN18.2 Antibody（25C7A5-HZ1） is a monoclonal antibody targeting human, mouse and monkey CLDN18.2 and can be used in cancer research.

Anti-Human/Mouse/Monkey TL1A Antibody（1D1） is a monoclonal antibody targeting human, mouse and monkey TL1A and can be used in inflammation research.

Anti-Human/Rat VEGF Antibody（A.4.6.1） is a monoclonal antibody targeting human and rat VEGF and can be used in angiogenesis research.

Anti-Mouse VEGF Antibody（G6-31） is a monoclonal antibody targeting mouse VEGF and can be used in angiogenesis research.

Anti-Mouse DDR2 Antibody (DAB0065) is a monoclonal antibody targeting mouse DDR2 and can be used in tumor microenvironment research.

Anti-Human CD64 Antibody (H22) is a monoclonal antibody targeting human CD64 and can be used in immunological research.

ADC Control Human IgG1 kappa-vcMMAE is an HIV-targeting ADC used as a control for other ADCs in research.

Anti-Mouse CD37 Antibody (252-3) is a monoclonal antibody targeting mouse CD37 and can be used in immunological research.

Acalabrutinib (ACP-196), also known as ACP-196, is an orally available inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity. Upon administration, ACP-196 inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway. This prevents both B-cell activation and BTK-mediated activation of downstream survival pathways. This leads to an inhibition of the growth of malignant B cells that overexpress BTK. BTK, a member of the src-related BTK/Tec family of cytoplasmic tyrosine kinases, is overexpressed in B-cell malignancies; it plays an important role in B lymphocyte development, activation, signaling, proliferation and survival.

PF-01247324 is a selective and orally bioavailable Nav1.8 channel blocker [IC50: 196 nM].

EM12-FS is a cereblon (CRBN) ligand that binds to CRBN at His353 and acts as a molecular glue degrader of NTAQ1. It has a half-life of 196 minutes in human plasma.

JP-2-196 functions as a molecular glue handle, engaging with E3 ubiquitin ligases such as RNF126, LRSAM1, RNF40, MID2, RNF219, and RNF14 in an immunoprecipitation (IP) assay at a concentration of 10 µM. Additionally, JP-2-196 is utilized in the creation of diverse molecular glue degraders.

Antibacterialagent 196 (compound 6b) is a coumarin derivative featuring an oxime ether structure, and it demonstrates notable antifungal activity, with an EC50 value of 0.46 μg/mL against Rhizoctonia solani.

JP-2-196 (TFA) is a molecular glue handle that binds in vitro with E3 ubiquitin ligases [RNF126, LRSAM1, RNF40, MID2, and RNF14]. It is applicable in the synthesis of molecular glue degraders.

JP-2-196 hydrochloride is a covalent molecular glue degrader that specifically targets RNF126. It facilitates the formation of a ternary complex between RNF126 and target proteins (e.g., BRD4, AR-V7), promoting their ubiquitination and proteasomal degradation. JP-2-196 hydrochloride is being explored for potential applications in cancer research, such as prostate cancer and leukemia.

Fanotaprim is a dihydrofolate reductase (DHFR) inhibitor, suppressing the growth of T. gondii strains with a TgDHFR IC50 of 1.57 ± 0.11 nM, a hDHFR IC50 of 308 ± 71 nM, and a hDHFR to TgDHFR selectivity ratio of 196.

NG 25 is a type II kinase inhibitor that inhibits MAP4K2 and TAK1 (IC50s = 21.7 and 149 nM, respectively).1It also inhibits the Src family kinases Src and LYN (IC50s = 113 and 12.9 nM, respectively) and Abl family kinases (IC50s = 75.2 nM), as well as CSK, FER, and p38α (IC50s = 56.4, 82.3, and 102 nM, respectively). NG 25 (100 nM) prevents TNF-α-induced IKKα/β phosphorylation and IκB-α degradation in L929 cells. It inhibits secretion of IFN-α and IFN-β induced by CpG type B and CL097, respectively, in Gen2.2 cells in a concentration-dependent manner.2NG 25 decreases cell viability of HCT116KRASWT, and to a greater degree of HCT116KRASG13D, colorectal cancer cells in a concentration-dependent manner.3It also reduces tumor growth and increases the number of TUNEL-positive tumor cells in a CT26KRASG12Dmouse orthotopic model of colorectal cancer. 1.Tan, L., Nomanbhoy, T., Gurbani, D., et al.Discovery of type II inhibitors of TGFβ-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2)J. Med. Chem.58(1)183-196(2015) 2.Pauls, E., Shpiro, N., Peggie, M., et al.Essential role for IKKβ in production of type 1 interferons by plasmacytoid dendritic cellsJ. Biol. Chem. 287(23)19216-19228(2012) 3.Ma, Q., Gu, L., Liao, S., et al.NG25, a novel inhibitor of TAK1, suppresses KRAS-mutant colorectal cancer growth in vitro and in vivoApoptosis24(1-2)83-94(2019)

D-threo-PPMP is a glucosylceramide (GlyCer) synthetase inhibitor.1,2It is the active enanantiomer and enzymatic inhibitory component of the racemic DL-threo-PPMP . In MDCK kidney epithelial cells, D-threo-PPMP induces a 70% reduction in cell growthin vitroat 20 μM and significantly inhibits DNA synthesis at 3 μM.3[Matreya, LLC. Catalog No. 1865] 1.Shen, W., Henry, A.G., Paumier, K.L., et al.Inhibition of glucosylceramide synthase stimulates autophagy flux in neuronsJ. Neurochem.129(5)884-894(2014) 2.Lee, L., Abe, A., and Shayman, J.A.Improved inhibitors of glucosylceramide synthaseJ. Biol. Chem.274(21)14662-14669(1999) 3.Abe, A., Inokuchi, J.-i., Jimbo, M., et al.Improved inhibitors of glucosylceramide synthaseJ. Biochem.111(2)191-196(1992)

ICRF-196 is a Topoisomerase II Inhibitor and antineoplastic agent.

Amubarvimab (BRII-196) is a humanized recombinant antibody targeting the spike protein of SARS-CoV-2, with antiviral activity, used in studies of COVID-19 infection.